Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ).
On April 8, 2026, Radiopharm Theranostics reported that a Data Safety and Monitoring Committee had recommended advancing its 177Lu-RAD202 ‘HEAT’ Phase 1 trial for HER2‑positive advanced solid tumors to Cohort 3 at a higher 130mCi dose, following favorable safety data at lower levels. The company highlighted the rapid progression of the Australian trial, noting that dose escalation previously reached 75mCi by October 1, 2025, and stated that, based on current execution, it expects to complete the Phase 1 dose‑escalation phase by the end of 2026, potentially strengthening its position in the competitive HER2‑targeted radiopharmaceutical space.
The most recent analyst rating on (RADX) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.
Spark’s Take on RADX Stock
According to Spark, TipRanks’ AI Analyst, RADX is a Neutral.
The score is held down primarily by persistent losses and ongoing cash burn, despite a debt-free balance sheet. Technical indicators also remain bearish with the stock trading below key moving averages and a negative MACD. Valuation support is limited because the company is unprofitable (negative P/E) and offers no dividend yield.
To see Spark’s full report on RADX stock, click here.
More about Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited is a clinical‑stage radiotherapeutics company developing radiopharmaceutical products for diagnostic and therapeutic use in oncology, targeting areas of high unmet medical need. Listed on the ASX and Nasdaq, it is building a pipeline of peptide, small‑molecule and monoclonal antibody‑based agents across multiple solid tumor indications, including lung, breast, prostate and brain cancers.
Average Trading Volume: 169,666
Technical Sentiment Signal: Sell
Current Market Cap: $50.09M
See more insights into RADX stock on TipRanks’ Stock Analysis page.